Wednesday was a watershed day for US GLP-1 policy: the Trump administration scrapped the five-year Medicare BALANCE pilot after CVS projected $1.4B in 10-year costs, sending Lilly down 2% and Novo down 4%, while NPR reported 12M Americans each lost Wegovy and Zepbound coverage between 2025 and 2026. On the peptide science side, April 22 formally marked BPC-157, TB-500, Semax, Epitalon, and MOTS-c exiting the FDA's Category 2 list ahead of the July PCAC meeting. AACR's final days delivered distinctive peptide-drug-conjugate data — Avacta's AVA6103 showed 3x higher tumor selectivity than Enhertu in preclinical models, and Evaxion's EVX-01 personalized peptide vaccine achieved 75% ORR at 2 years in melanoma with Keytruda. AAN 2026 wrapped with a 22,000-patient migraine study showing GLP-1 agonists cut ED visits 10% and hospitalizations 14% vs topiramate. The week's takeaway: GLP-1 commercialization is consolidating around price-sensitive retail channels (Amazon One Medical launched Monday; Hims dropped 6%) while the broader peptide field advances on both regulatory and clinical fronts.